Do Traders Think Esperion Therapeutics Inc (ESPR) Can Keep Climbing Wednesday?

Esperion Therapeutics Inc (ESPR) stock is higher by 23.74% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Esperion Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ESPR!

See Full ESPR Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ESPR Stock Today?

Esperion Therapeutics Inc (ESPR) stock is flat 0.19% while the S&P 500 has risen 0.33% as of 10:16 AM on Wednesday, Mar 27. ESPR is flat $0.00 from the previous closing price of $2.70 on volume of 2,055,791 shares. Over the past year the S&P 500 is higher by 31.25% while ESPR has risen 61.31%. ESPR lost -$2.03 per share in the over the last 12 months.

More About Esperion Therapeutics Inc

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Click Here to get the full Stock Report for Esperion Therapeutics Inc stock.